Search
Search Results
-
Astrocytic accumulation of tau fibrils isolated from Alzheimer’s disease brains induces inflammation, cell-to-cell propagation and neuronal impairment
Accumulating evidence highlights the involvement of astrocytes in Alzheimer’s disease (AD) progression. We have previously demonstrated that human...
-
Rosuvastatin attenuates total-tau serum levels and increases expression of miR-124-3p in dyslipidemic Alzheimer's patients: a historic cohort study
microRNAs are candidate diagnostic biomarkers for Alzheimer's disease. This study aimed to compare Silymarin with Rosuvastatin and placebo on...
-
Tau in cerebrospinal fluid induces neuronal hyperexcitability and alters hippocampal theta oscillations
Alzheimer’s disease (AD) and other tauopathies are characterized by the aggregation of tau into soluble and insoluble forms (including tangles and...
-
TREM2 and microglia exosomes: a potential highway for pathological tau
Tau pathology appears to spread along neuronal networks via the template misfolding of tau by pathological tau conformations. The mechanisms...
-
Impact of APOE on amyloid and tau accumulation in argyrophilic grain disease and Alzheimer’s disease
Alzheimer’s disease (AD), characterized by the deposition of amyloid-β (Aβ) in senile plaques and neurofibrillary tangles of phosphorylated tau...
-
AdipoRon Ameliorates Synaptic Dysfunction and Inhibits tau Hyperphosphorylation through the AdipoR/AMPK/mTOR Pathway in T2DM Mice
There is growing evidence showing that adiponectin (APN) can improve Alzheimer’s disease(AD)-like pathological changes by improving insulin...
-
Identical tau filaments in subacute sclerosing panencephalitis and chronic traumatic encephalopathy
Subacute sclerosing panencephalitis (SSPE) occurs in some individuals after measles infection, following a symptom-free period of several years. It...
-
The APOE-R136S mutation protects against APOE4-driven Tau pathology, neurodegeneration and neuroinflammation
Apolipoprotein E4 ( APOE4 ) is the strongest genetic risk factor for late-onset Alzheimer’s disease (LOAD), leading to earlier age of clinical onset...
-
Alterations in iron content, iron-regulatory proteins and behaviour without tau pathology at one year following repetitive mild traumatic brain injury
Repetitive mild traumatic brain injury (r-mTBI) has increasingly become recognised as a risk factor for the development of neurodegenerative...
-
Mical modulates Tau toxicity via cysteine oxidation in vivo
Tau accumulation is clearly linked to pathogenesis in Alzheimer’s disease and other Tauopathies. However, processes leading to Tau fibrillization and...
-
A novel D-amino acid peptide with therapeutic potential (ISAD1) inhibits aggregation of neurotoxic disease-relevant mutant Tau and prevents Tau toxicity in vitro
BackgroundAlzheimer’s disease (AD), the most common form of dementia, is a progressive neurodegenerative disorder that mainly affects older adults....
-
CSF tau microtubule-binding region identifies pathological changes in primary tauopathies
Despite recent advances in fluid biomarker research in Alzheimer’s disease (AD), there are no fluid biomarkers or imaging tracers with utility for...
-
Whole-brain modeling of the differential influences of amyloid-beta and tau in Alzheimer’s disease
BackgroundAlzheimer’s disease is a neurodegenerative condition associated with the accumulation of two misfolded proteins, amyloid-beta (A
... 
-
Tau Aggregation Inhibiting Peptides as Potential Therapeutics for Alzheimer Disease
Alzheimer disease (AD) is the most common progressive neurodegenerative disorder. AD causes enormous personal and economic burden to society as...
-
Alzheimer risk gene product Pyk2 suppresses tau phosphorylation and phenotypic effects of tauopathy
BackgroundGenetic variation at the PTK2B locus encoding the protein Pyk2 influences Alzheimer’s disease risk. Neurons express Pyk2 and the protein...
-
Loss of tau expression attenuates neurodegeneration associated with α-synucleinopathy
BackgroundNeuronal dysfunction and degeneration linked to α-synuclein (αS) pathology is thought to be responsible for the progressive nature of...
-
Tau activation of microglial cGAS–IFN reduces MEF2C-mediated cognitive resilience
Pathological hallmarks of Alzheimer’s disease (AD) precede clinical symptoms by years, indicating a period of cognitive resilience before the onset...
-
Cerebrospinal fluid α-synuclein adds the risk of cognitive decline and is associated with tau pathology among non-demented older adults
BackgroundThe role of α-synuclein in dementia has been recognized, yet its exact influence on cognitive decline in non-demented older adults is still...
-
P-tau subgroups in AD relate to distinct amyloid production and synaptic integrity profiles
BackgroundWe previously identified four Alzheimer’s disease (AD) subgroups with increasingly higher cerebrospinal fluid (CSF) levels of tau...
-
PP2A-associated tau hyperphosphorylation was involved in sevoflurane induced neonatal neurotoxicity
BackgroundThe effects of sevoflurane anesthesia on childhood neurodevelopment and adult brain function have attracted increasing scientific...
